文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

积极与保守筛查及确认试验对低或中风险患者拔管时间的影响:一项随机临床试验

Effect of aggressive vs conservative screening and confirmatory test on time to extubation among patients at low or intermediate risk: a randomized clinical trial.
PubMed 文献 · Intensive Care Med · 2024-02-14
一句话结论对拔管失败低或中风险且计划HFNC的患者,积极筛查(PaO2/FiO2>180、PEEP 10)联合保守SBT可缩短拔管时间且不增加再插管率。

这项多中心随机试验纳入原发呼吸衰竭、拔管失败低至中风险且计划HFNC预防治疗的患者,比较保守或积极筛查(PaO2/FiO2≥150且PEEP≤8 vs PaO2/FiO2>180且PEEP 10)与保守或积极SBT(压力支持5 cmH2O+PEEP 0 vs 压力支持8+PEEP 5)四种组合。因安全原因,中期分析时停止积极-积极组随机化,最终分析884例至少进行1次SBT的患者。积极筛查组拔管时间中位数更低(p<0.001),简单脱机率分别为45.7%、76.78%、71.65%和91%(p<0.001),再插管率无显著差异(p=0.431)。作者认为,积极筛查联合预防性PEEP与保守SBT可缩短拔管时间而不增加再插管率。

要点

  • 拔管失败低或中风险且计划HFNC的患者中,积极筛查组(PaO2/FiO2>180且PEEP 10维持至SBT)拔管时间中位数低于保守筛查组(p<0.001)。
  • 四组简单脱机率分别为45.7%、76.78%(205例)、71.65%和91%(p<0.001),积极筛查联合保守SBT组最高。
  • 再插管率(拔管后7天内)四组间无显著差异(p=0.431)。
  • 积极-积极组因安全原因在中期分析时停止随机化,最终该组仅100例。
  • 共884例至少进行1次SBT的患者纳入分析,四组分别为256、267、261和100例。

适用人群与场景

  • 原发呼吸衰竭、拔管失败低至中风险、计划HFNC预防治疗的患者。
  • 至少进行1次SBT的患者纳入分析,共884例。
  • 四组例数:保守-保守组256例、保守-积极组267例、积极-保守组261例、积极-积极组100例。

诊断标准与关键阈值

  • 保守筛查:PaO2/FiO2≥150且PEEP≤8 cmH2O。
  • 积极筛查:PaO2/FiO2>180且PEEP 10维持至SBT。
  • 保守SBT:压力支持5 cmH2O+PEEP 0 cmH2O。
  • 积极SBT:压力支持8 cmH2O+PEEP 5 cmH2O。

处置流程与药物剂量

  • 四组干预组合:保守筛查+保守SBT;保守筛查+积极SBT;积极筛查+保守SBT;积极筛查+积极SBT。
  • 所有患者计划接受HFNC预防治疗。
  • 积极-积极组(积极筛查+积极SBT)因安全原因在中期分析时停止随机化。

研究设计与关键结果

  • 研究类型:多中心随机临床试验,884例至少进行1次SBT的患者纳入分析。
  • 主要终点:积极筛查组拔管时间中位数更低(p<0.001);简单脱机率四组分别为45.7%、76.78%(205例)、71.65%和91%(p<0.001)。
  • 次要终点:拔管后7天内再插管率四组间无显著差异(p=0.431)。
  • 积极-积极组因安全原因在中期分析时停止随机化,该组100例。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验。
  • 局限:积极-积极组因安全原因在中期分析时停止随机化。

对床旁实践的改变

  • 对拔管失败低或中风险且计划HFNC的患者,作者认为积极筛查(PaO2/FiO2>180且PEEP 10维持至SBT)联合保守SBT可缩短拔管时间而不增加再插管率。
  • 积极-积极组因安全原因提前终止,提示该组合不宜作为常规策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: This study aimed to determine the best strategy to achieve fast and safe extubation.

METHODS: This multicenter trial randomized patients with primary respiratory failure and low-to-intermediate risk for extubation failure with planned high-flow nasal cannula (HFNC) preventive therapy. It included four groups: (1) conservative screening with ratio of partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) ≥ 150 and positive end-expiratory pressure (PEEP) ≤ 8 cmH2O plus conservative spontaneous breathing trial (SBT) with pressure support 5 cmH2O + PEEP 0 cmH2O); (2) screening with ratio of partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) ≥ 150 and PEEP ≤ 8 plus aggressive SBT with pressure support 8 + PEEP 5; (3) aggressive screening with PaO2/FiO2 > 180 and PEEP 10 maintained until the SBT with pressure support 8 + PEEP 5; (4) screening with PaO2/FiO2 > 180 and PEEP 10 maintained until the SBT with pressure support 5 + PEEP 0. Primary outcomes were time-to-extubation and simple weaning rate. Secondary outcomes included reintubation within 7 days after extubation.

RESULTS: Randomization to the aggressive-aggressive group was discontinued at the interim analysis for safety reasons. Thus, 884 patients who underwent at least 1 SBT were analyzed (conservative-conservative group, n = 256; conservative-aggressive group, n = 267; aggressive-conservative group, n = 261; aggressive-aggressive, n = 100). Median time to extubation was lower in the groups with aggressive screening (p < 0.001). Simple weaning rates were 45.7%, 76.78% (205 patients), 71.65%, and 91% (p < 0.001), respectively. Reintubation rates did not differ significantly (p = 0.431).

CONCLUSION: Among patients at low or intermediate risk for extubation failure with planned HFNC, combining aggressive screening with preventive PEEP and a conservative SBT reduced the time to extubation without increasing the reintubation rate.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hernández Martínez G, Rodriguez P, Soto J, et al. Effect of aggressive vs conservative screening and confirmatory test on time to extubation among patients at low or intermediate risk: a randomized clinical trial. Intensive Care Med. 2024. PMID: 38353714. doi:10.1007/s00134-024-07330-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。